Table 1.
Clinical Characteristics of Patients for Ovarian Cancer Patients Diagnosed with and without Brain Metastases
| Variables | Patients, No. | Proportion of Brain Metastases, % | Survival among Patients with Brain Metastases, Median (IQR), mo | |||
|---|---|---|---|---|---|---|
| OC (N=29512) | OC with Brain Metastases (N=89) | OC without Brain Metastases (N=29423) | Among Entire cohort | Among Metastatic subset | ||
| Age (years) | ||||||
| Median (range) | 62 (18-102) | - | -- | |||
| 18-58 | 12359 | 28 | 12331 | 0.23 | 2.72 | 3(2-11.25) |
| ≥59 | 17153 | 61 | 17092 | 0.36 | 2.42 | 2 (0-10) |
| Marital status | ||||||
| Married | 14188 | 35 | 14153 | 0.25 | 2.26 | 3(1-12) |
| Single | 6565 | 22 | 6542 | 0.34 | 2.77 | 2(0-10.5) |
| Divorced | 2990 | 8 | 2982 | 0.27 | 2.18 | 1 (0-2) |
| Widowed | 4424 | 17 | 4408 | 0.38 | 2.51 | 2(0-7) |
| Unknown | 1345 | 7 | 1338 | 0.52 | 4.38 | 4(2-10) |
| Race | ||||||
| White | 23792 | 70 | 23722 | 0.29 | 2.50 | 2(0-9) |
| Black | 2692 | 12 | 2692 | 0.45 | 2.64 | 2(0.25-36) |
| Others | 2852 | 5 | 2847 | 0.18 | 1.75 | 2(0-18.5) |
| Unknown | 176 | 2 | 174 | 1.14 | 22.22 | 10.5(NA) |
| Origin recode | ||||||
| Hispanic | 4136 | 11 | 4125 | 0.27 | 2.43 | 6(2-12) |
| None-hispanic | 25376 | 78 | 25298 | 0.31 | 2.52 | 2(0-10) |
| Laterality | ||||||
| Unilateral | 15441 | 32 | 15409 | 0.42 | 1.51 | |
| Bilateral | 9362 | 23 | 9339 | 0.25 | 1.24 | 6(2-15) |
| Unknown | 4709 | 34 | 4675 | 0.72 | 2.05 | 1.5(0-6.25) |
| Tumor staging | ||||||
| I | 6966 | 0 | 6966 | 0 | 0 | NA- |
| II | 2435 | 0 | 2435 | 0 | 0 | NA |
| III | 10799 | 1 | 10798 | 0.01 | 33.33 | 6(NA) |
| IV | 8239 | 87 | 8152 | 1.06 | 2.47 | 2(0-10) |
| Unknown | 1073 | 1 | 1072 | 0.09 | 4.76 | 2(NA) |
| T staging | ||||||
| T1 | 7811 | 11 | 7800 | 0.14 | 6.55 | 2(0-12) |
| T2 | 3724 | 9 | 3265 | 0.24 | 3.01 | 4(1-12.5) |
| T3 | 15084 | 26 | 15058 | 0.17 | 1.22 | 5(2-12.75) |
| Unknown | 2893 | 43 | 2850 | 1.49 | 4.57 | 2(0-6) |
| N staging | ||||||
| N0 | 20246 | 45 | 20201 | 0.22 | 2.73 | 2(0-12.5) |
| N1 | 6202 | 21 | 6181 | 0.34 | 1.91 | 2(0.5-9) |
| Unknown | 3064 | 23 | 3041 | 0.75 | 2.89 | 3(1-7) |
| Histology | ||||||
| Epithelial neoplasms | 26303 | 67 | 26236 | 0.25 | 2.12 | 2(1-10) |
| Gonadal neoplasms | 1297 | 2 | 1295 | 0.15 | 5.00 | 21.5(12-NA) |
| Others | 1071 | 3 | 1068 | 0.28 | 2.07 | 12(2-NA) |
| Unknown | 841 | 17 | 824 | 2.02 | 8.37 | 0(0-2.5) |
| Treatmenta | ||||||
| Others | 3371 | 37 | 3334 | 1.10 | 3.98 | 0(0-2) |
| CSR | 213 | 13 | 200 | 6.10 | 29.55 | 12(5.5-39) |
| RS | 24 | 3 | 21 | 12.50 | 60.00 | 2(2-NA) |
| SC | 17127 | 5 | 17122 | 0.03 | 0.35 | 20(18-56.5) |
| RC | 77 | 15 | 62 | 19.48 | 31.25 | 4(2-10) |
| R | 38 | 6 | 32 | 15.79 | 30.00 | 0.5(0-2.5) |
| S | 5647 | 2 | 5645 | 0.04 | 1.18 | 4.5(3-NA) |
| C | 3015 | 8 | 3007 | 0.27 | 0.90 | 3(0.25-7) |
| Surgery | ||||||
| U/BSO | 12146 | 14 | 12132 | 0.12 | 2.77 | 12(7.5-30.75) |
| Cytoreductive | 10360 | 9 | 10351 | 0.09 | 0.83 | 12(2-35.5) |
| Others | 505 | 0 | 505 | 0 | 0 | NA |
| No | 6501 | 66 | 6435 | 1.02 | 3.50 | 2(0-4) |
| Radiotherapy | ||||||
| No | 29160 | 52 | 29108 | 0.18 | 1.52 | 1.5 (0-6) |
| Yes | 352 | 37 | 315 | 10.51 | 31.62 | 4(2-12) |
| Chemotherapy | ||||||
| No | 9080 | 48 | 9032 | 0.53 | 4.27 | 1(0-2) |
| Yes | 20432 | 41 | 20391 | 0.20 | 1.69 | 9(2-16) |
| Radiation Sequence with surgeryb | ||||||
| RBS | 15 | 1 | 14 | 6.67 | 14.29 | 9(NA) |
| RAS | 235 | 17 | 218 | 7.23 | 35.42 | 10(2-14) |
| RBAS | 1 | 0 | 1 | 0 | 0 | NA |
| Others | 29261 | 71 | 29190 | 0.24 | 2.03 | 2(0-6) |
| Bone Met | ||||||
| No | 29160 | 61 | 29099 | 0.21 | 1.90 | 2(0-11) |
| Yes | 310 | 24 | 286 | 7.74 | 7.74 | 3(0-8.5) |
| Unknown | 42 | 4 | 38 | 9.52 | 18.18 | 2.5(0.5-9.75) |
| Liver Met | ||||||
| No | 27249 | 62 | 27187 | 0.23 | 4.47 | 2(0-10.5) |
| Yes | 2120 | 21 | 2099 | 0.99 | 0.99 | 2(0.5-5) |
| Unknown | 143 | 6 | 137 | 4.20 | 15.00 | 2(0-12.75) |
| Lung Met | ||||||
| No | 27538 | 49 | 27489 | 0.18 | 2.85 | 2(0.5-11) |
| Yes | 1773 | 37 | 1736 | 2.09 | 2.09 | 2(0-8) |
| Unknown | 201 | 3 | 198 | 1.49 | 5.36 | 0(NA) |
| CA125 | ||||||
| Normal | 2654 | 4 | 2650 | 0.15 | 5.13 | 16.5(6-54.75) |
| Elevated | 20241 | 49 | 20192 | 0.24 | 1.80 | 2(0-8) |
| Unknown | 6617 | 36 | 6581 | 0.54 | 4.85 | 2(0-11.5) |
| Insurance situation | ||||||
| No | 1096 | 7 | 1089 | 0.64 | 4.55 | 2(0-2) |
| Yes | 27927 | 77 | 27846 | 0.28 | 2.31 | 2(0-12) |
| Unknown | 489 | 5 | 484 | 1.02 | 8.33 | 3(2.5-6.5) |
| Residence type | ||||||
| Rural | 482 | 1 | 481 | 0.21 | 1.67 | 2(NA) |
| Urban | 3376 | 12 | 3364 | 0.36 | 3.10 | 1(0-2.75) |
| Metropolitan | 25630 | 76 | 25554 | 0.30 | 2.46 | 2.5(0.25-12) |
| Unknown | 24 | 0 | 24 | 0 | 0 | NA |
Abbreviations: OC: ovary cancer; IQR: interquartile range; CI: confidence interval.
a including CSR: chemotherapy, surgery, and radiotherapy, RS: radiotherapy and surgery, SC: surgery and chemotherapy, RC: radiotherapy and chemotherapy, R: radiotherapy alone, S: surgery alone, C: chemotherapy alone, others: other treatment except for radiotherapy, surgery, and chemotherapy.
bincluding RBS: radiation before surgery, RAS: radiotherapy after surgery, RBAS: radiotherapy before and after surgery, others: without surgery or radiotherapy or unknown sequence.